Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results.

@article{Barkhof2007MagneticRI,
  title={Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results.},
  author={F. Barkhof and C. Polman and E. Radue and L. Kappos and M. Freedman and G. Edan and H. Hartung and D. Miller and X. Montalban and Peter A. Poppe and M. de Vos and F. Lasri and L. Bauer and S. Dahms and K. Wagner and C. Pohl and R. Sandbrink},
  journal={Archives of neurology},
  year={2007},
  volume={64 9},
  pages={
          1292-8
        }
}
  • F. Barkhof, C. Polman, +14 authors R. Sandbrink
  • Published 2007
  • Medicine
  • Archives of neurology
    • BACKGROUND In the Betaseron/Betaferon in Newly Emerging Multiple Sclerosis for Initial Treatment (BENEFIT) study, interferon beta-1b delayed conversion to multiple sclerosis in patients with a first clinical event and at least 2 clinically silent brain magnetic resonance imaging (MRI) lesions. OBJECTIVE To examine detailed MRI findings from the first 2 years of this trial. DESIGN Double-blind, placebo-controlled, randomized, parallel-group, multicenter, phase 3 study. SETTING Ninety-eight… CONTINUE READING
    View on PubMed
    jamanetwork.com
    48 Citations
    Background Citations
    10
    Methods Citations
    5
    Results Citations
    2

    Supplemental Clinical Trials

    Interventional Clinical Trial
    BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study
    This study will primarily compare the long-term effects of an early and continued treatment with Betaferon/Betaseron (patients who were treated with active medication during the… Expand
    ConditionsMultiple Sclerosis
    InterventionDrug
    Bayer
    August 2002 - May 2008
    Explore Further
    Discover more papers related to the topics discussed in this paper

    Tables and Topics from this paper

    Tables

    Explore Further: Topics Discussed in This Paper

    48 Citations
    Citation Type

    Citation Type

    Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes
    • 14
    • PDF
    Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial
    • 335
    Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study.
    • 31
    • PDF
    MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study
    • 29
    Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome
    • 14
    Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis
    • 34
    • PDF
    Interferon-β-1b
    • 39
    MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials
    • 63
    Subcutaneous interferon β-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study
    • 20
    • PDF
    Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials
    • 85

    References

    SHOWING 1-10 OF 28 REFERENCES
    Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study
    • 1,002
    Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.
    • 1,438
    • PDF
    Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis
    • 1,875
    • PDF
    Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.
    • 467
    • PDF
    Effect of interferon‐β1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: Results of a European multicenter, randomized, double‐blind, placebo‐controlled trial
    • 139
    Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes
    • 584
    Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial
    • 241
    T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment.
    • 99
    • PDF
    Using gadolinium‐enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis
    • 338
    Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis
    • 36